JP2019517505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517505A5 JP2019517505A5 JP2018563009A JP2018563009A JP2019517505A5 JP 2019517505 A5 JP2019517505 A5 JP 2019517505A5 JP 2018563009 A JP2018563009 A JP 2018563009A JP 2018563009 A JP2018563009 A JP 2018563009A JP 2019517505 A5 JP2019517505 A5 JP 2019517505A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- administered
- months
- dose
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130733A JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2023176091A JP2024020202A (ja) | 2016-06-02 | 2023-10-11 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344866P | 2016-06-02 | 2016-06-02 | |
| US62/344,866 | 2016-06-02 | ||
| US201662382839P | 2016-09-02 | 2016-09-02 | |
| US62/382,839 | 2016-09-02 | ||
| PCT/US2017/035521 WO2017210473A1 (en) | 2016-06-02 | 2017-06-01 | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130733A Division JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517505A JP2019517505A (ja) | 2019-06-24 |
| JP2019517505A5 true JP2019517505A5 (enExample) | 2020-07-16 |
| JP7641704B2 JP7641704B2 (ja) | 2025-03-07 |
Family
ID=59067913
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563009A Active JP7641704B2 (ja) | 2016-06-02 | 2017-06-01 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2022130733A Pending JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2023176091A Pending JP2024020202A (ja) | 2016-06-02 | 2023-10-11 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130733A Pending JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2023176091A Pending JP2024020202A (ja) | 2016-06-02 | 2023-10-11 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11299543B2 (enExample) |
| EP (2) | EP4248989A3 (enExample) |
| JP (3) | JP7641704B2 (enExample) |
| KR (3) | KR20230119265A (enExample) |
| CN (1) | CN109476752A (enExample) |
| AU (2) | AU2017274444B2 (enExample) |
| BR (1) | BR112018074619A2 (enExample) |
| CA (1) | CA3026246A1 (enExample) |
| DK (1) | DK3464368T3 (enExample) |
| ES (1) | ES2951650T3 (enExample) |
| FI (1) | FI3464368T3 (enExample) |
| HU (1) | HUE063911T2 (enExample) |
| IL (1) | IL263165A (enExample) |
| MX (2) | MX390955B (enExample) |
| NZ (1) | NZ748650A (enExample) |
| PL (1) | PL3464368T3 (enExample) |
| PT (1) | PT3464368T (enExample) |
| SG (2) | SG11201810454YA (enExample) |
| SI (1) | SI3464368T1 (enExample) |
| WO (1) | WO2017210473A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3322732A2 (en) | 2015-07-13 | 2018-05-23 | Cytomx Therapeutics Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| BR112018074619A2 (pt) | 2016-06-02 | 2019-03-06 | Bristol Myers Squibb Co | uso de um anticorpo anti-pd-1 em combinação com um anticorpo anti-cd30 em tratamento com câncer |
| CA3077729A1 (en) * | 2017-10-13 | 2019-04-18 | Seattle Genetics, Inc. | Modulating the immune response using antibody-drug conjugates |
| US11572405B2 (en) * | 2018-01-12 | 2023-02-07 | Bristol-Myers Squibb Company | Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer |
| UA130009C2 (uk) * | 2018-05-07 | 2025-10-15 | Генмаб А/С | Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу |
| TW202519270A (zh) | 2018-06-07 | 2025-05-16 | 美商思進公司 | 喜樹鹼結合物 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| WO2020135559A1 (en) * | 2018-12-26 | 2020-07-02 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
| KR20220069964A (ko) | 2019-09-25 | 2022-05-27 | 씨젠 인크. | 조혈암의 치료를 위한 항-cd30 adc, 항-pd-1 및 화학치료제 조합 |
| BR112022011268A2 (pt) | 2019-12-09 | 2022-09-06 | Seagen Inc | Terapia de combinação com antagonista de liv1-adc e pd1 |
| CN111407894B (zh) * | 2020-02-21 | 2022-04-29 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种治疗复发/难治t细胞淋巴瘤的新型联合靶向药物 |
| IL298155A (en) * | 2020-05-13 | 2023-01-01 | Seagen Inc | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates |
| AU2022231068A1 (en) | 2021-03-01 | 2023-08-17 | Nantbio, Inc. | Anti-cd30 monoclonal antibodies and chimeric antigen receptors |
| CN118987233A (zh) * | 2024-08-08 | 2024-11-22 | 武汉科技大学 | 治疗经典型霍奇金淋巴瘤的药物组合物及其用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| CN101490085A (zh) * | 2006-06-12 | 2009-07-22 | 特鲁比昂药品公司 | 具有效应功能的单链多价结合蛋白 |
| CL2007003622A1 (es) * | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP2927240A1 (en) | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| PL2699264T3 (pl) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1 |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| AU2014214843A1 (en) * | 2013-02-07 | 2015-05-21 | Immunomedics, Inc. | Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
| ES2878749T3 (es) * | 2013-02-20 | 2021-11-19 | Innate Pharma | Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| CN111423511B (zh) | 2013-05-31 | 2024-02-23 | 索伦托药业有限公司 | 与pd-1结合的抗原结合蛋白 |
| ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| EP3066127A1 (en) * | 2013-11-06 | 2016-09-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| US20160303231A1 (en) * | 2013-12-11 | 2016-10-20 | Robert Iannone | Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor |
| PE20160953A1 (es) | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| FI3463457T3 (fi) | 2016-06-02 | 2023-09-12 | Bristol Myers Squibb Co | Pd-1-esto nivolumabilla refraktaarinen hodgkinin lymfoomassa |
| BR112018074619A2 (pt) | 2016-06-02 | 2019-03-06 | Bristol Myers Squibb Co | uso de um anticorpo anti-pd-1 em combinação com um anticorpo anti-cd30 em tratamento com câncer |
-
2017
- 2017-06-01 BR BR112018074619A patent/BR112018074619A2/pt unknown
- 2017-06-01 KR KR1020237026623A patent/KR20230119265A/ko not_active Ceased
- 2017-06-01 AU AU2017274444A patent/AU2017274444B2/en active Active
- 2017-06-01 SG SG11201810454YA patent/SG11201810454YA/en unknown
- 2017-06-01 PL PL17730629.7T patent/PL3464368T3/pl unknown
- 2017-06-01 FI FIEP17730629.7T patent/FI3464368T3/fi active
- 2017-06-01 KR KR1020187037834A patent/KR102710067B1/ko active Active
- 2017-06-01 PT PT177306297T patent/PT3464368T/pt unknown
- 2017-06-01 NZ NZ748650A patent/NZ748650A/en unknown
- 2017-06-01 SI SI201731383T patent/SI3464368T1/sl unknown
- 2017-06-01 CA CA3026246A patent/CA3026246A1/en active Pending
- 2017-06-01 WO PCT/US2017/035521 patent/WO2017210473A1/en not_active Ceased
- 2017-06-01 JP JP2018563009A patent/JP7641704B2/ja active Active
- 2017-06-01 EP EP23174305.5A patent/EP4248989A3/en not_active Withdrawn
- 2017-06-01 DK DK17730629.7T patent/DK3464368T3/da active
- 2017-06-01 KR KR1020247031531A patent/KR20240145059A/ko not_active Ceased
- 2017-06-01 ES ES17730629T patent/ES2951650T3/es active Active
- 2017-06-01 US US16/306,282 patent/US11299543B2/en active Active
- 2017-06-01 HU HUE17730629A patent/HUE063911T2/hu unknown
- 2017-06-01 CN CN201780048015.7A patent/CN109476752A/zh active Pending
- 2017-06-01 MX MX2018014610A patent/MX390955B/es unknown
- 2017-06-01 EP EP17730629.7A patent/EP3464368B1/en active Active
- 2017-06-01 SG SG10202101062YA patent/SG10202101062YA/en unknown
-
2018
- 2018-11-21 IL IL263165A patent/IL263165A/en unknown
- 2018-11-27 MX MX2022003571A patent/MX2022003571A/es unknown
-
2022
- 2022-04-07 US US17/715,875 patent/US20220298243A1/en not_active Abandoned
- 2022-08-18 JP JP2022130733A patent/JP2022176973A/ja active Pending
-
2023
- 2023-10-11 JP JP2023176091A patent/JP2024020202A/ja active Pending
-
2024
- 2024-10-30 AU AU2024227762A patent/AU2024227762A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517505A5 (enExample) | ||
| JP2019517504A5 (enExample) | ||
| JP2019503387A5 (enExample) | ||
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| JP2017507155A5 (enExample) | ||
| JP2019517498A5 (enExample) | ||
| JP2018500332A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2014515036A5 (enExample) | ||
| IL313952A (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment | |
| JP2021501776A5 (enExample) | ||
| JP2019517512A5 (enExample) | ||
| IL312038A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| JP2019508433A5 (enExample) | ||
| JP2015500822A5 (enExample) | ||
| Cohen | Myeloma: next generation immunotherapy | |
| IL307925A (en) | Combination of an anti-pd-1 antibody and an anti-tissue factor (tf) antibody-drug conjugate for use in the treatment of cancer | |
| JP2014505056A5 (enExample) | ||
| Perini et al. | Brentuximab vedotin in CD30+ lymphomas | |
| Wolska-Washer et al. | Emerging antibody-drug conjugates for treating lymphoid malignancies | |
| Sadaka et al. | Proteasome inhibition for antibody-mediated allograft rejection | |
| Borghaei et al. | Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin) | |
| Kato et al. | Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia | |
| JPWO2018213260A5 (enExample) | ||
| Paillassa et al. | Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer. |